Genor Biopharma Holdings Ltd

67N0

Company Profile

  • Business description

    Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.

  • Contact

    690 Bibo Road
    Room 501-02, Building 6
    Pudong New District
    Shanghai201203
    CHN

    https://www.genorbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    17

Stocks News & Analysis

stocks

Nvidia: Collaboration with Intel might bring some goodwill with the US

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
stocks

What now for Santos after takeover offer collapses?

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.
stocks

Morningstar initiates coverage on small cap ASX REIT

Coverage of ASX listed REIT as investor interest in property continues to grow.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,061.2061.30-0.67%
CAC 407,853.591.02-0.01%
DAX 4023,639.4135.12-0.15%
Dow JONES (US)46,315.27172.850.37%
FTSE 1009,216.6711.44-0.12%
HKSE26,545.10106.590.40%
NASDAQ22,631.48160.750.72%
Nikkei 22545,045.81143.540.32%
NZX 50 Index13,231.663.23-0.02%
S&P 5006,664.3632.400.49%
S&P/ASX 2008,773.5075.00-0.85%
SSE Composite Index3,820.0911.57-0.30%

Market Movers